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Abstract
Background: The aim of this study was to evaluate the value of 18F–FDG PET/CT (PET/CT) and MRI for local and/or
whole-body restaging of adenoid cystic carcinoma of the head and neck (ACC).
Methods: Thirty-six patients with ACC underwent conventional MRI of the head and neck and a whole-body PET/CT
and were analysed with regards to detection of a local tumor recurrence, lymph node or distant metastases. A consensus
interpretation of all available imaging data was used as reference standard. Sensitivity, specificity, diagnostic accuracy,
positive and negative predictive values were calculated for MRI and PET/CT.
Results: The sensitivity of PET/CT and MRI was 96% (89%), specificity 89% (89%), PPV 96% (96%), NPV 89% (73%) and
accuracy 94% (89%) for detection of local tumors. Additionally, PET/CT revealed lymph node metastases in one patient
and distant metastases in 9/36 patients. In three patients secondary primaries were found.
Conclusions: Whole-body PET/CT in addition to MRI of the head and neck improves detection of local tumour and
metastastic spread in ACC.
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Background
Adenoid cystic carcinoma (ACC) is a rare type of
cancer mainly located within secretory glands, most
commonly the minor but also the major salivary
glands of the head and neck [1]. Each year, about
1200 people are diagnosed with ACC in the United
States. ACC is a (generally) well-differentiated and
slowly growing tumour with a relatively indolent but
relentless course. The tumour is characterised by a
marked tendency for perineural invasion with the risk
of incomplete resection and (late) local and distant
recurrences [2–4].
Due to the tendency of this tumour to spread along
nerve tracts, the complete radical resection of the primary
tumour as the main therapeutic approach is very challen-
ging and results in frequent local recurrences. Adjuvant
radiotherapy is commonly applied after surgery and leads
to improved local control. Furthermore, in some cases,
surgery is not feasible to tumour location, therefore
primary radiation (e.g. using high linear energy transfer
(LET) beams (fast neutrons or carbon ions) [5–7] is the
only treatment option. Chemotherapy has only limited
effects in trials so far [8–10]. Sub-cellular and genetic
characteristics of the ACC can be used for targeted
systemic therapy efforts and have in part already been
considered in clinical trials [11]. Hence, so far no break-
through has been achieved in systemic therapy for this
entity.
In contrast to 10- to 20-year survival rates (about 40%
at 15 years), 5-year survival rates in patients with ACC are
high with around 89% [12, 13], reflecting a prolonged
course of metastatic disease and late local recurrences.
Another specific feature of ACC is the relatively rare
occurrence of regional lymph nodes metastases although
micro metastases might be detected in a relevant number
of patients if neck dissection is performed [14]. Even after
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successful local therapy distant metastases often occur
metachronously in lung and sometimes in the liver
and limit long-term prognosis. According to the exist-
ing literature, distant metastases in ACC are rare at
initial diagnosis and depend on disease duration and
primary site, although some authors state that current
diagnostic means might not be sensitive enough to
detect them [15, 16].
Due to the diffuse growth pattern the detection of
local recurrence, especially differentiation between scar
formation, radiation effects and vital tumour is limited
and routine imaging techniques (computed tomography
(CT), magnetic resonance imaging (MRI) and ultrasound
(US)) suffer from low specificity [17–19]. Thus, in case
of suspected recurrence it is anticipated that metabolic
information provided by 18F–fluorodeoxyglucose (FDG)
positron emission tomography (PET) could improve the
distinction between benign and malignant lesions [17,
20, 21]. Published reports on FDG uptake in ACC are
rare [22–25], and many of these are only case series with
a small number of patients. The existing literature hints
that most squamous cell carcinomas are intensely FDG
avid, whereas adenoid cystic carcinoma and mucoepider-
moid carcinoma show variable uptake depending on the
grade of differentiation [26]. In a recently published
study by Kim et al. [27] the pretreatment SUVmax of
FDG-PET was as a predictor of distant metastasis in
ACC of the head and neck.
In this study we evaluate the diagnostic accuracy of
FDG PET/CT and MRI for restaging ACC patients in
a relatively large population with particular focus on
local and whole-body staging.
Materials and methods
Patient population
Imaging data of 36 consecutive patients (19 females, 17
males, mean age 57 ± 12 years) suffering from ACC of
the head and neck (histologically confirmed initial locali-
sations: salivary glands (parotid and submandibular
gland; n = 18), small salivary glands: oropharynx (n = 7),
trachea (n = 2), paranasal sinus (n = 4), eye socket (n = 2)
and upper jaw (n = 3)) were retrospectively analysed.
The diagnostic imaging procedures were performed
within the context of routine clinical procedures within
a short time interval in the case of restaging of ACC
when suspecting recurrences (n = 16) or approximately
two months after local tumour resection prior to
adjuvant radiation therapy (n = 20). Therefore, ethics
approval was waived.
MRI studies
All patients underwent a conventional MRI of the head
and neck. MRI was performed in a whole-body 1.5 Tesla
MR scanner using the following sequence protocol:
1. A T1-weighted Spin Echo (T1 SE) in coronal slice
orientation (time of repetition (TR) 425 ms, echo
time TE) 15 ms, slice thickness 5 mm, matrix size
512, field of view (FOV) 280).
2. An axial T1-weighted SE (TR 455 ms, TE 11 ms,
slice thickness 5 mm, matrix size 512, FOV 230).
3. An axial T2-weighted SE (TR 3900 ms, TE 87 ms,
slice thickness 5 mm, matrix size 512, FOV 260).
4. An axial post contrast T1-weighted SE with fat sat-
uration (TR 474 ms, TE 11 ms, slice thickness
5 mm, matrix size 512, FOV 230) after i.v. adminis-
tration of 0.1 mmol/kg body weight of gadobutrol
(Gadovist, Bayer Healthcare, Leverkusen, Germany).
5. A coronal post-contrast T1-weighted SE TR (TR
710 ms, TE 15 ms, slice thickness 5 mm, matrix size
512, FOV 280).
PET/CT studies
Dedicated head and neck and whole-body FDG PET/
CT scans were performed using a Biograph mCT™
(Siemens AG, Healthcare Sector, Erlangen, Germany).
The head and neck scan was performed 60 ± 5 min
after tracer injection (weight-dependent FDG dose,
mean activity 290 ± 45 MBq) and 40 s after intraven-
ous contrast agent injection (60 ml Ultravist®; Bayer
Healthcare Deutschland, Leverkusen, Germany) from
the skull base to the aortic arch (slice thickness
3 mm). To minimize artefacts, the patient’s arms were
placed beside the body. Afterwards, the patients were en-
couraged to place the arms over their head for the following
whole-body examination. The scan ranged from the upper
thorax to the thighs and was performed 70 s after injection
of an additional dose of 70 ml contrast agent (slice thick-
ness 5 mm). In both protocols, the manufacturer-supplied
dose reduction techniques CareDose 4D™and CareKV™
were used (presets 210 mAs, 120 kV; Siemens AG). Blood
glucose was below 150 mg/dl at the time of tracer injection.
PET data were acquired for 4 min per bed position in the
head and neck area and for 2 min per bed position in the
rest of the body. For reconstruction, attenuation weighted
ordered-subsets expectation maximization (AW-OSEM) it-
erative algorithm with 4 iterations and 8 subsets, Gaussian
filter with 4.0 mm full width at half maximum (FWHM)
and scatter correction were used.
Immediately after the PET scan a thoracic full-dose CT
scan was performed in the forced inspiratory position with
the following parameters: 120 kV, automatic mA/s adjust-
ment (Care Dose 4D™, preset: 70 mAs), 5-mm slice thick-
ness; reconstruction in lung window.
Image analysis
Board certified physicians in nuclear medicine and radi-
ology visually interpreted the PET/CT and MRI data,
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being blinded to the results of the other imaging exami-
nations. The presence of residual/recurrent tumours,
number of regional lymph node metastases and distant
metastases were counted separately in both CT and
MRI.
On MR images, a lesion in a suspected site of tumour
with a hypo- to isotense signal in the T1-weighted image,
a slightly to markedly hyperintense signal in the T2-
weighted image and an enhancement in the contrast-
enhanced T1-weighted image was considered as malig-
nant. On CT and MR images, increased short-axis diam-
eter (>10 mm), central necrosis, irregular shape and the
lack of a fatty hilus sign and increased contrast agent up-
take were considered as signs of malignancy in lymph
nodes.
On the hybrid images (PET/CT), central necrosis, focal
soft tissue increase and focal FDG-uptake were considered
as indicators of malignancy in local cancer recurrence. In
a PET-specific semi-quantitative approach, the maximum
standardized uptake values (SUVmax) of all tumour le-
sions/suspected sites of metastasis or focally increased
tracer uptake visually defined above the mediastinal blood
pool were determined by drawing spherical volumes of
interest (VOI) that closely encircled a lesion.
Reference standard
A consensus interpretation of all available imaging data
(prior examinations and follow-up examinations (median
12, range 3–105 months): MRI of the head and neck,
thoracic CT, whole-body-PET/CT, ultrasound) adopted
by all readers was used as reference standard.
Statistical analysis
Sensitivity, specificity, positive predictive value (PPV),
negative predictive value (NPV) and diagnostic accuracy
were calculated for MRI, PET, CT and PET/CT using
Microsoft Excel (15.29.1).
Results
Recurrent or residual tumour
A recurrent or residual tumour was present in 27 of the
36 patients according to the reference standard. MRI
detected 24 of 27 tumour lesions. In the remaining three
cases with tumour recurrence the MRI findings were
indistinct (an illustrative example is given in Fig. 1). MRI
was negative in 8 of 9 the patients without signs of tumour
and indistinct in one patient (Fig. 2). Thus, the sensitivity
was 89%, specificity 89%, PPV 96%, NPV 73% and accur-
acy 89%.
PET/CT detected 26 of 27 tumour lesions with
increased FDG uptake (Fig. 3). One patient did not show
any pathologically increased tracer uptake in the tumour
lesion (in the former parotid gland area with penetration
of the base of the skull, the mastoid and neurocranium)
that was only detected on MRI (Fig. 4). Mean SUVmax
across all lesions was 6.8 ± 3.4 (median 5.7, range 2.0–
15.0). PET/CT was negative in 8 of 9 patients without a
tumour. PET/CT was false-positive in one patient
(Fig. 5). Thus, the corresponding sensitivity was 96%,
specificity 89% and accuracy 94%. PPV and NPV calcu-
lated to 96% and 89%, respectively.
Lymph node metastases
In one patient, regional cervical lymph node metastases
were dectected in accordance with the reference standard.
On the PET component this patient with the primary
tumour in the right parotid gland presented increased
FDG uptake (SUVmax 6.0), whereas the the lymph node
was according to CT and MRI size criteria not suspicious.
Distant metastases
PET/CT detected distant metastases in 9 out of 36
patients with manifestations in the lung (n = 8), bone (n =
5), adrenal gland (n = 1), kidney (n = 1), and liver (n = 1),
as well as distant lymph node metastases (n = 1) in the
mediastinum (primary localisation in the submandibular
Fig. 1 ACC recurrence: PET/CT imaging was true-positive, indistinctive finding on MRI. Patient after resection of an adenoid cystic carcinoma in
the left parotid gland and after combined neutron/proton therapy. Recurrence is seen on the fused PET/CT (a) and PET image (b) with a focally
increased FDG-uptake (arrow), but not on the contrast-enhanced T1-weighted MR image (c). In MRI, the finding was evaluated as
radiation necrosis
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gland). Corresponding mean SUVmax was 3.9 ± 2.3
(median 3.8, range 1.2–9.9). Four patients presented
lung metastases that were not known at time of first
diagnosis but discriminated by PET/CT after local
tumour resection prior to adjuvant radiation therapy.
In all patients with distant metastases, the lesions
could be defined as malignant on combined PET/CT.
In case of lung metastases the CT was indistinctive in
2 patients (differential diagnosis: granuloma), but the
PET component helped the lesion characterization as
malignant. In two cases with disseminated lung me-
tastases, the smallest malignant lesions could only be
detected on CT.
All patients with distant metastases had no
synchronical regional lymph node metastases, and 4/9
patients had no local recurrence.
In addition to the main diagnosis a secondary primary
carcinoma was found in three patients. In these cases
with histopathologically confirmed cervical carcinoma,
prostate carcinoma and breast cancer preferential
treatment was conducted.
Discussion
This study demonstrates the high sensitivity of whole-
body FDG PET/CT in detecting both recurrent/residual
tumours and regional metastatic spread in patients with
ACC. FDG PET/CT also outperformed head neck MRI
for local staging and restaging. Moreover, the whole
body imaging approach enables the detection of distant
metastases even at an early stage and in the follow up.
Local tumours were present in 75% of the patients in
our study population. Of these, 63% had residual
tumours, and 37% had tumour recurrence. The detec-
tion rate of a residual or recurrent tumour on PET/CT
was highly accurate with only one false-negative and one
false-positive finding. PET/CT was only false-negative in
one patient with tumour recurrence in the head and
neck area. PET/CT was false-positive in only one case in
the head and neck area, possibly due to a physiological
hyperfunctional pharyngeal reaction and perfusion after
contralateral resection of the primary tumour. MRI had
four indistinct findings in the former local tumour
region. The diagnostic performance of PET/CT was
Fig. 2 No tumour recurrence: PET/CT imaging was true-negative, indistinctive finding on MRI. Patient after multiple resections of recurrent
tumours of a left buccal adenoid cystic carcinoma. A hyperintense lesion is seen on the contrast-enhanced T1-weighted MR image (c)
(arrow), but there was no pathological finding on the fused PET/CT (a) and PET image (b). The follow-up confirmed no recurrence
Fig. 3 ACC tumour remaining: PET/CT and MR imaging was true-positive. Patient after resection of an adenoid cystic carcinoma, now with a
tumour remnant on the right root of the tongue prior to neutron therapy. The tumour mass is seen on the fused PET/CT (a) and PET image (b)
with a focally increased FDG-uptake (SUVmax 14.1) and contrast-enhanced T1-weighted MR image (c) (arrow)
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comparable to MRI in local restaging with a higher
sensitivity (96% v. 89%) and diagnostic accuracy (94% vs.
89%) due to less indistinct findings.
Locoregional lymph node metastases were present in
only one patient in our study population with a true-
positive finding on PET and false-negative finding on CT
or MRI due to size criteria. This low incidence of locore-
gional lymph node metastases is in line with previous
reports that described that an ACC rarely metastasises
to regional lymph nodes [28, 29]. The ability of PET to
detect metastases in lymph nodes that are inconspicuous
in morphologic imaging has been shown in a variety of
cancers [17, 30, 31].
Combined whole-body PET/CT detected all distant
metastases in our study. There were only two cases with
disseminated metastases of the lung in which not all of
the CT-detectable lesions were also FDG positive due to
the limited spatial resolution. In two patients the lung
metastases showed a pathologically increased FDG up-
take, whereas the CT was indistinctive (differential diag-
nosis: granuloma). Distant metastases were present in
25% of the patients in our study population. Surprisingly,
in the patient group with the primary examination after
local tumour resection prior to radiation therapy, 11% of
the patients already showed distant metastases in the
lung. In three patients secondary carcinomas were found
with PET/CT allowing early therapeutic interventions.
Previous reports have described overall rate of distant
metastases in 25 to 50% of patients with ACC [29], but
the occurrence mainly depends on the follow-up period.
In fact, in 35 to 50% of patients with ACC, distant
metastases were usually found within a follow-up period
of more than 15 to 20 years [32]. These studies, which
were published several years ago, used conventional
diagnostics such as X-ray with comparably low specifi-
city and sensitivity for staging the lung of ACC patients.
Therefore, slow-growing metastases might have been
misinterpreted as newly occurred metastases at a late
time point, although other diagnostic imaging methods
like CT might have shown a metastatic disease at an
earlier time point in their clinical course or even at time
of initial diagnosis.
According to Spiro et al. [29], large primary tumour
size and locoregional treatment failure are the most
Fig. 4 ACC recurrence: PET/CT imaging was false-negative and MRI true-positive. Patient after multiple resections of the primary and recurrent tu-
mours of an ACC in the right parotid gland area. A false-negative finding is seen on the on the fused PET/CT (a) and PET image (b), but there
was a true-positive finding on the contrast-enhanced T1-weighted MR image (c) with a hyperintense tumour recurrence (arrow)
Fig. 5 No tumour recurrence: PET/CT imaging was false-positive and MRI true-negative. Patient after resection of an ACC in the right parotid
gland and mandibula. A contralateral false-positive finding is seen on the PET (b) and fused PET/CT image (a) with a focally increased FDG-uptake
(SUVmax 5.4; arrow), but there was no pathological finding on the contrast-enhanced T1-weighted MR image (c)
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important predisposing factors for outcome. However,
distant metastases may develop despite successful locor-
egional tumour therapy. As in our study, the lungs are
the most commonly reported sites to harbour distant
metastases. These patients may remain asymptomatic
for a long time during their clinical course. However, the
onset of symptoms or the development of other visceral
metastases usually results in a short survival period.
Thus, whole body imaging seems advisable in restaging
and follow-up of ACC patients to better understand the
course of disease and find optimal therapy strategies, as
was recently highlighted in a report from Tewari et al.
[33].
In our study, almost all lesions were FDG-avid, and
the majority showed a moderately to high FDG uptake.
Previously published literature predominantly case
reports or case series on FDG uptake in this advancing
but relentlessly growing tumour with a propensity for
perineural invasion comprise only very few patients [22–
25]. In larger studies ACC often represent only a
minority within a group of mixed head and neck cancers
[25]. The existing literature of experience with PET im-
aging show that adenoid cystic carcinoma and mucoepi-
dermoid carcinoma showed variable FDG-uptake
depending on the grade of differentiation [26] in
comparison to most squamous cell carcinomas that
showed high uptake. Due to the complex development
of the disease in patients with ACC an appropiate diag-
nostic imaging is required. The evaluation of changes in
tissues and structures in the tumour environment,
especially after extended tumour resection in the head
and neck area, surgical procedures with transplants or
external beam radiotherapy, is a big challenge since US,
conventional CT and MRI provide mainly just morpho-
logical information and exactly here PET imaging can
improve the diagnostic work-up as a tool that depict
metabolism information.
A limitation of this study is the nevertheless limited
number of patients due to the rarity of this malignant
disease. This study cohort comprised 36 patients which
is more than any other study. The small sample size did
not permit an analysis of the FDG uptake depending on
the histopathological ACC subtypes (cribriform, solid
and tubular). Another limitation is the reference stand-
ard lacking histopathological confirmation. However, the
consensus interpretation (adopted by all readers) based
on profound imaging data including prior and follow-up
examinations (median 12, range 3–105 months).
Interestingly, FDG PET/CT depicted all lesions visual-
ized by the standard imaging tools head and neck is
MRI and if applicable thoracic CT. This underlines the
potential of whole-body FDG-PET/CT improving the
diagnostic accuracy of restaging ACC. Whereas MRI is
commonly needed preoperatively for the assessment of
tumour delineation and relevant tumour invasion of
surrounding structures it is not a routine whole-body
imaging technique. The advantages of FDG-PET/CT are
the examination of the whole body at one time and at a
high sensitivity. Furthermore, our study demonstrates
that due to certain weaknesses the conventional CT and
MR imaging of the head and neck could benefit from
the additional metabolism information provided by the
PET component. Thus, in the time of installation of inte-
grated whole-body PET/MR systems, it would be of
interest to determine whether a single whole-body PET/
MRI could replace a whole-body PET/CT by combining
the advantages of both modalities.
Conclusions
Our study demonstrates the potential of FDG-PET/CT
as important diagnostic tool in the restaging of ACC pa-
tients. FDG PET/CT has a higher sensitivity and diag-
nostic accuracy than MRI for the loco-regional tumour
staging and provides valuable additional information as a
whole-body technique.
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